Neupogen (Filgrastim)

Filgrastim binds to the G‑CSF receptor on hematopoietic stem and progenitor cells, triggering signaling pathways that stimulate the proliferation, differentiation, and activation of neutrophil precursors, thereby increasing the number and function of circulating neutrophils.

The prescribed dose of Neupogen is individualized by the treating clinician based on the specific indication, patient weight, renal function, and response to therapy. Dosing regimens are detailed in the product’s prescribing information and should not be altered without medical guidance.

Safety data for filgrastim in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the prescriber in consultation with the patient.

To request Neupogen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

The primary alternative to filgrastim is pegfilgrastim, a long‑acting pegylated form that requires a single injection per chemotherapy cycle. Filgrastim typically requires daily dosing but offers flexibility in dose adjustment, whereas pegfilgrastim provides convenience with fewer injections but less dosing flexibility.

Neupogen must be stored refrigerated between 2 °C and 8 °C. Protect the vial from light, keep it in the original packaging, and avoid freezing or shaking. Once reconstituted, it should be used promptly according to the manufacturer’s instructions.

Neupogen is supplied as a sterile injection solution for subcutaneous administration. The vial is reconstituted with the provided diluent, and the dose is injected into the subcutaneous tissue of the abdomen, thigh, or upper arm, following aseptic technique.

Serious adverse events include splenic rupture, acute respiratory distress syndrome, and severe allergic reactions such as anaphylaxis. Patients should be educated to seek immediate medical attention if they experience sudden abdominal pain, difficulty breathing, or signs of a severe allergic response.

Neupogen is contraindicated in individuals with known hypersensitivity to filgrastim or any excipients in the formulation. It should also be avoided in patients receiving live vaccines and used with caution in those with sickle cell disease or other conditions that predispose to vaso‑occlusive complications.